Acute Myocardial Infarction: Curations of Cardiovascular Original Research A Bibliography
Curators: Aviva Lev-Ari, PhD, RN and Larry H Bernstein, MD, FCAP
This article covers CURATIONS on one topic in Cardiology: Acute Myocardial Infarction. It represents a Bibliography on the subject matter using the Methodology of Curation.
The e-Reader is advised to read the article that describes what is this methodology and what makes it particularly appropriate for analysis, synthesis, interpretation and exposition of Medical Research Findings.
conceived: NEW Definition for Co-Curation in Medical Research
The e-Reader is advised to review the Curation methodology applied to case studies on Cardiovascular Diseases in the following volume:
Series A: e-Books on Cardiovascular Diseases
Series A Content Consultant: Justin D Pearlman, MD, PhD, FACC
VOLUME TWO
Cardiovascular Original Research:
Cases in Methodology Design for Content Co-Curation
The Art of Scientific & Medical Curation
by
Justin D Pearlman, MD, PhD, FACC
Larry H Bernstein, MD, FCAP
Aviva Lev-Ari, PhD, RN
Acute Myocardial Infarction: Curations of Cardiovascular Original Research A Bibliography from the Open Access Online Scientific Journal
http://pharmaceuticalintelligence.com
- A Software Agent for Diagnosis of ACUTE MYOCARDIAL INFARCTION
Isaac E. Mayzlin, Ph.D, David Mayzlin, Larry H. Bernstein, M.D
http://pharmaceuticalintelligence.com/2012/08/12/1815/
- Response to Rosuvastatin in Patients With Acute Myocardial Infarction: Hepatic Metabolism and Transporter Gene Variants Effect
Aviva Lev-Ari, PhD, RN
- MicroRNA in Serum as Bimarker for Cardiovascular Pathologies: acute myocardial infarction, viral myocarditis, diastolic dysfunction, and acute heart failure
Aviva Lev-Ari, PhD, RN
- Acute and Chronic Myocardial Infarction: Quantification of Myocardial Perfusion Viability – FDG-PET/MRI vs. MRI or PET alone
Justin Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN
- Atherosclerosis Independence: Genetic Polymorphisms of Ion Channels Role in the Pathogenesis of Coronary Microvascular Dysfunction and Myocardial Ischemia (Coronary Artery Disease (CAD))
Larry H Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
- Myocardial Damage in Cardiovascular Disease: Circulating MicroRNA-208b and MicroRNA-499
Aviva Lev-Ari, PhD, RN
- Intracoronary Transplantation of Progenitor Cells after Acute MI
Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
http://pharmaceuticalintelligence.com/2013/11/02/progenitor-cells-coronary-graft-after-ami/
- Myocardial Infarction: The New Definition After Revascularization
Aviva Lev-Ari, PhD, RN
- Coronary Circulation Combined Assessment: Optical Coherence Tomography (OCT),Near-Infrared Spectroscopy (NIRS) and Intravascular Ultrasound (IVUS) – Detection of Lipid-Rich Plaque and Prevention of Acute Coronary Syndrome (ACS)
Justin Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN
Larry H Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
http://pharmaceuticalintelligence.com/2013/06/30/troponin-i-in-acute-decompensated-heart-failure/
- Microchemistry Implant Device for Early Detection of Acute Coronary Syndrome
Larry H Bernstein, MD, FACP
http://pharmaceuticalintelligence.com/2013/03/26/microchemistry-implant-device/
Larry H Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
http://pharmaceuticalintelligence.com/2013/06/30/troponin-i-in-acute-decompensated-heart-failure/
- Acute Chest Pain/ER Admission: Three Emerging Alternatives to Angiography and PCI – Corus CAD, hs cTn, CCTA
Aviva Lev-Ari, PhD, RN
- Clinical Trials Results for Endothelin System: Pathophysiological role in Chronic Heart Failure, Acute Coronary Syndromes and MI – Marker of Disease Severity or Genetic Determination?
Aviva Lev-Ari, PhD, RN
- Amplifying Information Using S-Clustering and Relationship to Kullback-Liebler Distance: An Application to Myocardial Infarction
Reporter and curator: Larry H Bernstein, MD, FCAP
http://pharmaceuticalintelligence.com/2012/09/22/amplifying-information-using-s-clustering/
- Human embryonic pluripotent stem cells and healing post-myocardial infarction
Larry H. Bernstein, MD, FCAP
- Diagnostic Value of Cardiac Biomarkers
Larry H Bernstein, MD, FCAP
http://pharmaceuticalintelligence.com/2014/01/04/diagnostic-value-of-cardiac-biomarkers/
- On-Hours vs Off-Hours: Presentation to ER with Acute Myocardial Infarction – Lower Survival Rate if Off-Hours
Aviva Lev-Ari, PhD, RN
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.